全文获取类型
收费全文 | 3338篇 |
免费 | 254篇 |
国内免费 | 37篇 |
专业分类
耳鼻咽喉 | 35篇 |
儿科学 | 141篇 |
妇产科学 | 63篇 |
基础医学 | 381篇 |
口腔科学 | 48篇 |
临床医学 | 346篇 |
内科学 | 813篇 |
皮肤病学 | 36篇 |
神经病学 | 269篇 |
特种医学 | 151篇 |
外科学 | 528篇 |
综合类 | 30篇 |
一般理论 | 3篇 |
预防医学 | 258篇 |
眼科学 | 93篇 |
药学 | 255篇 |
中国医学 | 4篇 |
肿瘤学 | 175篇 |
出版年
2021年 | 39篇 |
2020年 | 38篇 |
2019年 | 28篇 |
2018年 | 69篇 |
2017年 | 40篇 |
2016年 | 38篇 |
2015年 | 58篇 |
2014年 | 59篇 |
2013年 | 146篇 |
2012年 | 140篇 |
2011年 | 147篇 |
2010年 | 95篇 |
2009年 | 93篇 |
2008年 | 196篇 |
2007年 | 207篇 |
2006年 | 196篇 |
2005年 | 171篇 |
2004年 | 179篇 |
2003年 | 172篇 |
2002年 | 184篇 |
2001年 | 41篇 |
2000年 | 35篇 |
1999年 | 43篇 |
1998年 | 50篇 |
1997年 | 45篇 |
1996年 | 28篇 |
1995年 | 39篇 |
1994年 | 32篇 |
1993年 | 33篇 |
1992年 | 24篇 |
1991年 | 33篇 |
1990年 | 33篇 |
1989年 | 42篇 |
1988年 | 41篇 |
1987年 | 40篇 |
1986年 | 29篇 |
1985年 | 37篇 |
1984年 | 52篇 |
1983年 | 60篇 |
1982年 | 63篇 |
1981年 | 60篇 |
1980年 | 53篇 |
1979年 | 32篇 |
1978年 | 30篇 |
1977年 | 33篇 |
1976年 | 35篇 |
1975年 | 25篇 |
1973年 | 25篇 |
1972年 | 22篇 |
1971年 | 22篇 |
排序方式: 共有3629条查询结果,搜索用时 29 毫秒
1.
2.
3.
There is a sharp difference in how one views TCR structure–function–behaviour dependent on whether its recognition of major histocompatibility complex‐encoded restriction elements (R) is germline selected or somatically generated. The generally accepted or Standard model is built on the assumption that recognition of R is by the V regions of the αβ TCR, which is not driven by allele specificity, whereas the competing model posits that recognition of R is allele‐specific. The establishing of allele‐specific recognition of R by the TCR would rule out the Standard model and clear the road to a consideration of a competing construct, the Tritope model. Here, the case for allele‐specific recognition (germline selected) is detailed making it obvious that the Standard model is untenable. 相似文献
4.
5.
Liam Masterson James Howard Jazmina Gonzalez-Cruz Christopher Jackson Catherine Barnett Lewis Overton Howard Liu Rahul Ladwa Fiona Simpson Margie McGrath Ben Wallwork Terry Jones Christian Ottensmeier Melvin L.K. Chua Chris Perry Rajiv Khanna Benedict Panizza Sandro Porceddu Matt Lechner 《International journal of cancer. Journal international du cancer》2020,146(8):2305-2314
Now is an exciting era of development in immunotherapy checkpoint inhibitors and their effect on the treatment of NPC. While the general prognosis of R/M disease is poor, immunotherapy offers some promise in a malignancy associated with EBV and characterized by a peritumoural immune infiltrate. Our study aims to review past and on-going clinical trials of monoclonal antibody therapies against the checkpoint inhibitors (e.g. PD1 and CTLA-4), in R/M NPC. All randomized and nonrandomized controlled trials involving immune checkpoint inhibitor interventions for treatment of NPC were included in the study. We utilized a validated “risk of bias” tool to assess study quality. Four separate Phase I–II trials report the potential of PD1 inhibitor treatment for patients with NPC. Within the observed groups, camrelizumab combined with chemotherapy achieved an objective response in 91% of patients as first-line treatment for metastatic NPC (PFS 68% at 1-year) but this was associated with a high rate of grade >3 adverse events (87%; CTCAE version 4.03). The remaining three studies focused on recurrent NPC disease in patients who had received at least one line of prior chemotherapy. Within this group, camrelizumab monotherapy achieved an objective response in 34% of patients (PFS 27% at 1-year; range across all three studies 20.5–34%). No NPC trial has yet reported on specific outcomes for non-PD1 checkpoint inhibitors but 11 on-going studies include alternative targets (e.g. PD-L1/CTLA-4) as combination or monotherapy treatments. In considering checkpoint immunotherapies for NPC, initial results show promise for anti-PD1 interventions. Further phase I–III trials are in progress to clarify clinical outcomes, fully determine safety profiles, and optimize drug combinations and administration schedules. 相似文献
6.
7.
8.
9.
Laura Coots Daras Anne Deutsch Melvin J. Ingber Jennifer Gaudet Hefele Jennifer Perloff 《Topics in stroke rehabilitation》2021,28(1):61-71
ABSTRACT
Background
Stroke is the leading cause for admission to the nearly 1,200 Inpatient Rehabilitation Facilities (IRFs) nationally in the US. For many patients, post-acute care is an important component of their rehabilitation. Several quality measures have been publicly reported for post-acute care providers, including hospital readmissions. However, to date none have focused on specific medical conditions, limiting the usability for patients and quality improvement. 相似文献10.